JCP
CBPO

Jabre Capital Partners’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Jabre Capital Partners’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,000
Closed -$1.25M – 135
2016
Q3 		$1.25M Buy
+10,000
New +$1.18M 0.17% 84

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Jabre Capital Partners's CBPO Position: Q4 2016 in Review

Jabre Capital Partners sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2016, closing a stake of 10,000 shares — an estimated $1.25M sold.

Jabre Capital Partners first reported a position in CBPO in Q3 2016 and held it in 1 quarter. The position peaked at $1.25M in Q3 2016. 143 funds tracked by Wall St. Rank hold CBPO as of Q4 2016.

  • Jabre Capital Partners reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2016 after selling out during the quarter.
  • Jabre Capital Partners sold 10,000 China Biologic Products Holdings, Inc. shares in Q4 2016, an estimated $1.25M.
  • Jabre Capital Partners first reported a position in China Biologic Products Holdings, Inc. in Q3 2016 and held it in 1 quarter.
  • Jabre Capital Partners's China Biologic Products Holdings, Inc. position peaked at $1.25M in Q3 2016.
  • 143 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2016.

Based on Jabre Capital Partners's 13F filing for Q4 2016, filed 14 Feb 2017.